CN101237854B - 将胰岛素输送到哺乳动物的脂构建体 - Google Patents

将胰岛素输送到哺乳动物的脂构建体 Download PDF

Info

Publication number
CN101237854B
CN101237854B CN2006800268447A CN200680026844A CN101237854B CN 101237854 B CN101237854 B CN 101237854B CN 2006800268447 A CN2006800268447 A CN 2006800268447A CN 200680026844 A CN200680026844 A CN 200680026844A CN 101237854 B CN101237854 B CN 101237854B
Authority
CN
China
Prior art keywords
biotin
insulin
lipid
construct
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800268447A
Other languages
English (en)
Chinese (zh)
Other versions
CN101237854A (zh
Inventor
J·R·劳
W·B·格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SDG Inc
Original Assignee
SDG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/384,659 external-priority patent/US7858116B2/en
Priority claimed from US11/384,728 external-priority patent/US7871641B2/en
Application filed by SDG Inc filed Critical SDG Inc
Priority claimed from PCT/US2006/019119 external-priority patent/WO2006127361A2/en
Publication of CN101237854A publication Critical patent/CN101237854A/zh
Application granted granted Critical
Publication of CN101237854B publication Critical patent/CN101237854B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN2006800268447A 2005-05-23 2006-05-16 将胰岛素输送到哺乳动物的脂构建体 Expired - Fee Related CN101237854B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68387805P 2005-05-23 2005-05-23
US60/683,878 2005-05-23
US11/384,728 2006-03-20
US11/384,659 US7858116B2 (en) 1998-05-19 2006-03-20 Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal
US11/384,728 US7871641B2 (en) 1998-05-19 2006-03-20 Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal
US11/384,659 2006-03-20
PCT/US2006/019119 WO2006127361A2 (en) 2005-05-23 2006-05-16 Lipid construct for delivery of insulin to a mammal

Publications (2)

Publication Number Publication Date
CN101237854A CN101237854A (zh) 2008-08-06
CN101237854B true CN101237854B (zh) 2013-03-27

Family

ID=39661981

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2006800268447A Expired - Fee Related CN101237854B (zh) 2005-05-23 2006-05-16 将胰岛素输送到哺乳动物的脂构建体
CNA2006800268659A Pending CN101237855A (zh) 2005-05-23 2006-05-16 将干扰素输送到哺乳动物的脂构建体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2006800268659A Pending CN101237855A (zh) 2005-05-23 2006-05-16 将干扰素输送到哺乳动物的脂构建体

Country Status (5)

Country Link
US (1) US20100129428A1 (https=)
JP (1) JP5414270B2 (https=)
KR (1) KR101389226B1 (https=)
CN (2) CN101237854B (https=)
ZA (2) ZA200710056B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160271226A1 (en) * 2013-09-30 2016-09-22 Wockhardt Limited Pharmaceutical composition
CN107056802A (zh) * 2017-01-24 2017-08-18 河北百灵威超精细材料有限公司 N‑羟基硫代琥珀酰亚胺生物素酯及其衍生物的制备方法
WO2018169954A1 (en) * 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
KR20200106912A (ko) * 2018-01-05 2020-09-15 에스디지,인코포레이티드 당뇨병을 치료하기 위한 지질 기반 나노입자를 포함하는 조성물
WO2020210697A1 (en) * 2019-04-12 2020-10-15 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
KR102530032B1 (ko) 2019-09-18 2023-05-09 정원구 반려동물용 현탁액 조성물 및 이의 제조방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565889B2 (en) * 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
AU3999699A (en) * 1998-05-19 1999-12-06 Sdg, Inc. Targeted liposomal drug delivery system
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
WO2004021993A2 (en) * 2002-09-05 2004-03-18 The General Hospital Corporation Modified asialo-interferons and uses thereof
US20050026826A1 (en) 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system

Also Published As

Publication number Publication date
JP5414270B2 (ja) 2014-02-12
US20100129428A1 (en) 2010-05-27
CN101237855A (zh) 2008-08-06
JP2009507761A (ja) 2009-02-26
ZA200710056B (en) 2009-03-25
ZA200710055B (en) 2009-03-25
KR20080043742A (ko) 2008-05-19
CN101237854A (zh) 2008-08-06
KR101389226B1 (ko) 2014-04-25

Similar Documents

Publication Publication Date Title
US20250288521A1 (en) Orally bioavailable lipid-based constructs
DK2859015T3 (en) LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
US8846053B2 (en) Orally bioavailable lipid-based constructs
US10463616B2 (en) Lipid construct for delivery of insulin to a mammal
US9145453B2 (en) Orally bioavailable lipid-based constructs
EP3391876B1 (en) Lipid construct for delivery of insulin to a mammal
CN101237854B (zh) 将胰岛素输送到哺乳动物的脂构建体
US20220110870A1 (en) Lipid construct for delivery of insulin to a mammal
AU2012247063B2 (en) Lipid construct for delivery of insulin to a mammal
DK1883394T3 (en) Lipid construct for delivering insulin to a mammal
CA2864366C (en) Lipid construct comprising an amphipathic lipid, cholesterol, dicetyl phosphate, and a hepatocyte receptor binding molecule
HK1259503A1 (en) Orally bioavailable lipid-based constructs
AU2015249189A1 (en) Lipid construct for delivery of insulin to a mammal
HK1116396B (en) Lipid construct for delivery of insulin to a mammal
HK1116396A (en) Lipid construct for delivery of insulin to a mammal
HK1262603A1 (en) Lipid construct for delivery of insulin to a mammal
HK1262603B (en) Lipid construct for delivery of insulin to a mammal

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130327

CF01 Termination of patent right due to non-payment of annual fee